Saturday, March 05, 2016

efficacy of Majoon Ushba and Roghane Hindi in the management of psoriasis UNANI MEDICINE

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121250/

Psoriasis is a common dermatological disease affecting up to 1–2% of the world's population. It is associated with both organic and psychosocial complications like psoriatic arthropathy, nephritis, infection, hyperuricemia, hypoproteinemia, depression, and stress, and is responsible for hindering patients’ daily activities. The present study was conducted to assess the safety and efficacy of two pharmacopeial Unani formulations (Majoon Ushbaand Roghane Hindi) in the management of psoriasis on scientific parameters.

Majoon Ushba 5 g was administered orally twice daily andRoghane Hindi was applied locally twice daily. 

The severity of psoriasis and efficacy of the drug was assessed by the Psoriasis Area and Severity Index (PASI) Scale. The results of both groups were compared and analyzed statistically. The study showed significant reduction in the PASI score in the test group (P < 0.01) as compared to placebo. No obnoxious side effects were observed in the test group: toxicological parameters were within normal limits even after 2 months of treatment. It was therefore concluded that Majoon Ushba and Roghane Hindi are safe and effective in the management of psoriasis
Keywords: Majoon Ushba, Psoriasis Area and Severity Index Scale, psoriasis, Roghane Hindi, Unani formulations

No comments:

Post a Comment